Literature DB >> 15067090

Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR.

Anil Shanker1, Nathalie Auphan-Anezin, Patrick Chomez, Laurent Giraudo, Benoît Van den Eynde, Anne-Marie Schmitt-Verhulst.   

Abstract

Selection of immature CD4CD8 double-positive (DP) thymocytes for CD4 or CD8-lineage commitment is controlled by the interaction of the TCR with stromal cell-expressed peptide/MHC. We show that thymocyte-intrinsic genes influence the pattern of expression of a MHC class I-restricted transgenic (tg) TCR so that in DBA/2 mice, DP thymocytes with a characteristically high expression of tg TCR, infrequently transit to CD8 single-positive thymocytes. In contrast, in B10.D2 mice, the same tg TCR is expressed at lower levels on a subpopulation of DP thymocytes that more frequently transit to CD8 single-positive thymocytes. These characteristics were not influenced by thymic stromal components that control positive selection. Radiation chimeras reconstituted with a mixture of BM from tg TCR mice of the two genetic backgrounds revealed that the relative frequency of transit to the CD8 lineage remained thymocyte-intrinsic. Identifying the gene products whose polymorphism controls CD8 T cell development may shed new light on the mechanisms controlling T cell commitment/selection in mice other than the most studied "C57BL/6"-based strains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067090     DOI: 10.4049/jimmunol.172.8.5069

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.

Authors:  Xue Han; Peiying Ye; Liqun Luo; Linghua Zheng; Yang Liu; Lieping Chen; Shengdian Wang
Journal:  Cell Mol Immunol       Date:  2011-05-30       Impact factor: 11.530

Review 2.  Cooperativity of adaptive and innate immunity: implications for cancer therapy.

Authors:  Anil Shanker; Francesco M Marincola
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

3.  Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.

Authors:  Melissa Frick; Pierre Mouchacca; Grégory Verdeil; Yannick Hamon; Cyrille Billaudeau; Michel Buferne; Mathieu Fallet; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Claude Boyer
Journal:  Immunology       Date:  2016-11-02       Impact factor: 7.397

4.  Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.

Authors:  Anil Shanker; Michel Buferne; Anne-Marie Schmitt-Verhulst
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

5.  The thymic medulla: a unique microenvironment for intercellular self-antigen transfer.

Authors:  Christian Koble; Bruno Kyewski
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

6.  IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas.

Authors:  Michel Buferne; Lionel Chasson; Magali Grange; Amandine Mas; Fanny Arnoux; Mélanie Bertuzzi; Philippe Naquet; Lee Leserman; Anne-Marie Schmitt-Verhulst; Nathalie Auphan-Anezin
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

7.  Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Authors:  Jingjing Zhu; Céline G Powis de Tenbossche; Stefania Cané; Didier Colau; Nicolas van Baren; Christophe Lurquin; Anne-Marie Schmitt-Verhulst; Peter Liljeström; Catherine Uyttenhove; Benoit J Van den Eynde
Journal:  Nat Commun       Date:  2017-11-10       Impact factor: 14.919

8.  TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.

Authors:  Stefania Canè; Jacques Van Snick; Catherine Uyttenhove; Luc Pilotte; Benoit J Van den Eynde
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.